|
Tue, 08/06/2024 - 07:59 |
Moffitt Consortium Study Answers Questions About Long-Term Survivorship Following CAR T Treatment |
Moffitt |
|
Thu, 02/01/2024 - 22:23 |
Simple Blood Protein Tests Predict Which Lymphoma Patients Are Most Likely to Have Poor CAR T Outcomes |
Roswell Park Ca... |
|
Sun, 12/11/2022 - 10:16 |
CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial |
Dana Farber |
|
Thu, 11/03/2022 - 10:23 |
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022 |
Gilead Sciences |
|
Thu, 03/31/2022 - 17:41 |
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting |
Gilead Sciences |
|
Sat, 12/11/2021 - 07:43 |
Moffitt Study Shows Lymphoma Patients Can Benefit from Receiving CAR T Sooner |
Moffitt |
|
Tue, 02/02/2021 - 06:45 |
Moffitt Researchers Identify Why CAR T Therapy May Fail in Some Lymphoma Patients |
Moffitt |
|
Fri, 07/24/2020 - 15:49 |
FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL |
FDA |
|
Wed, 05/13/2020 - 12:53 |
Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting |
Gilead Sciences |
|
Mon, 03/30/2020 - 02:21 |
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan |
Daiichi Sankyo |
|
Wed, 12/11/2019 - 14:24 |
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma |
Gilead Sciences |
|
Mon, 12/09/2019 - 18:53 |
Kite and the CIBMTR Present Positive Findings From Real-World Use of Yescarta (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma |
Gilead Sciences |
|
Sat, 12/07/2019 - 14:17 |
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment |
Gilead Sciences |
|
Wed, 11/06/2019 - 09:48 |
Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019 |
Gilead Sciences |
|
Tue, 07/16/2019 - 07:27 |
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility |
Gilead Sciences |
|
Mon, 06/03/2019 - 09:56 |
Kite Announces New Yescarta Data From ZUMA-1 |
Gilead Sciences |
|
Sat, 06/01/2019 - 08:04 |
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia |
Gilead Sciences |
|
Fri, 05/31/2019 - 15:56 |
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Gilead Sciences |
|
Fri, 05/31/2019 - 14:23 |
-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- |
KaloBios Pharma... |
|
Wed, 05/15/2019 - 11:06 |
Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019 |
Gilead Sciences |
|
Wed, 04/24/2019 - 10:02 |
Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities |
Gilead Sciences |
|
Wed, 02/13/2019 - 07:48 |
Double NHS decision for CAR T cell immunotherapy in Scotland |
Cancer Research UK |
|
Thu, 10/04/2018 - 19:54 |
NHS England to fund engineered cell therapy for adults with aggressive lymphoma |
Cancer Research UK |
|
Tue, 10/02/2018 - 23:33 |
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma |
Daiichi Sankyo |
|
Thu, 08/30/2018 - 09:45 |
Engineered cell therapy given initial no for NHS in England |
Cancer Research UK |
